Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: A meta-analysis

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 43

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

351

HTML

3085

Figures (1-3)

204

Tables (1-2)

200

Sum=3840

Nov 21, 2012 (publication date) through Oct 18, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Nov 21, 2012; 18(43): 6290-6301
Published online Nov 21, 2012. doi: 10.3748/wjg.v18.i43.6290

Table 2 Sensitivity analysis

Index	Total HBeAg loss
Index	OR (95% CI)	P vaule
Excluding the minimum sample size trials[18]	1.64 (1.31, 2.05)	< 0.00010
Using random-effect model	1.68 (1.35, 2.09)	< 0.00001
Using fixed-effect model	1.69 (1.46, 1.97)	< 0.00001

OR: Odds ratio; HBeAg: Hepatitis B e antigen.

Citation: Su QM, Ye XG. Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: A meta-analysis. World J Gastroenterol 2012; 18(43): 6290-6301
URL: https://www.wjgnet.com/1007-9327/full/v18/i43/6290.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i43.6290